Key result
Editorial examines glycemic reduction strategies in type 2 diabetes without established cardiovascular complications.
Answers are grounded in this paper and cite their sources.
In two articles in this issue of the Journal, the members of the GRADE Study Research Group1,2 report the findings of the Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness (GRADE) Study, which involved participants who had type 2 diabetes without established cardiovascular complications. These articles have been awaited with great anticipation. Most advances related to cardiovascular benefit in the treatment of type 2 diabetes have been derived from cardiovascular outcome trials involving participants with previous cardiovascular disease, and these advances have been related to secondary prevention. On the basis of those trials, the availability of two new . . .
No takes yet. Share an insight, caveat, or question.
Rydén et al. (2022) conducted an editorial in Type 2 diabetes. Glycemia reduction approaches after metformin was evaluated. Glycemia reduction approaches in type 2 diabetes without established cardiovascular complications are discussed in this editorial accompanying the GRADE study.
Synapse has enriched 10 related papers. Consider them for comparative context: